Summarized by Daily Strand AI from peer-reviewed source
Scientists have long known that the bacteria living in our digestive tract can influence how colorectal cancer develops and responds to treatment. Now, researchers have uncovered exactly how certain gut bacteria help tumor cells survive chemotherapy. The study focuses on Klebsiella pneumoniae and similar bacteria, which shed a surface molecule called lipopolysaccharide, or LPS. The researchers discovered that this bacterial molecule promotes drug resistance in colorectal cancer by disabling p53, a crucial protein known for suppressing tumors.
The surprising part of this discovery is the mechanism. The bacterial molecules do not protect the cancer cells by interacting with them directly. Instead, they hijack the tumor microenvironment, which is the bustling neighborhood of noncancerous cells surrounding the tumor. When the bacterial LPS stimulates immune cells called macrophages and structural cells called fibroblasts, these neighboring cells become unwitting accomplices to the cancer.
The stimulated macrophages release tiny biological packages known as extracellular vesicles. These packages travel to the cancer cells and cause the vital p53 proteins to break down. Without enough p53 to regulate cell life and death, the cancer cells become significantly more resistant to chemotherapy drugs.
Colorectal cancer is one of the most common cancers worldwide, and tumors that resist chemotherapy represent a major hurdle for oncologists. This research opens the door to entirely new treatment strategies. If drug developers can find a way to block the communication between gut bacteria, immune cells, and the tumor, they might be able to restore the power of standard chemotherapy. Furthermore, the researchers found that patients who maintained specific p53 activity linked to this process had better survival rates after chemotherapy, suggesting doctors could eventually use these markers to predict treatment success.
However, it is important to view these results with cautious optimism. The current findings rely heavily on early laboratory models, such as cells grown in a dish, along with correlative patient data. The study does not include clinical trials or explicit human interventional metrics. Moving forward, scientists will need to test these mechanisms in clinical settings to confirm if targeting gut bacteria can truly turn the tide against drug-resistant colon cancer.
Interested in Oncology?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.